TLL-018 not checked

Hangzhou Highlightll Pharmaceutical Co., Ltd · Sequence 1 · Sequence 2

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
6 active
12 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.”In the company’s words, NCT06396026 on ClinicalTrials.gov
Tested for
Chronic Spontaneous Urticaria (CSU) (2 trials), Chronic Spontaneous Urticaria, Rheumatoid Arthritis, Atopic Dermatitis (AD), Rheumatoid Arthritis (RA)
Main trialPhase 3
“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.”In the company’s words, NCT06396026 on ClinicalTrials.gov
Other names
Sequence 1 · Sequence 2 · Sequence 3 · extended-release tablet · immediate-release tablet

Other drugs for Chronic Spontaneous Urticaria (CSU)

All 23 drugs for Chronic Spontaneous Urticaria (CSU)

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 23 Oct 2025 A Study of Efficacy and Safety of TLL-018 in CSU Participants
Phase 3Active, not recruiting 31 Dec 2026 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis
Phase 2/3Not yet recruiting 30 Sep 2029 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2Enrolling by invitation 31 Jul 2027 TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
Phase 2Not yet recruiting 31 Dec 2027 A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
Phase 1/2Not yet recruiting 31 Dec 2027 A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
Phase 3Completed 15 Jan 2026 A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
Phase 2Completed 19 Dec 2022 The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
Phase 2Completed 1 Dec 2024 The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Phase 1Completed 28 Aug 2023 Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects
Phase 1Completed 30 Aug 2023 Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
Phase 1Completed 7 Sep 2023 Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TLL-018

Following is part of Solo: you see every change to TLL-018 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in